Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Candel Therapeutics, Inc.NASDAQ: CADL
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow growth accelerates
Q1 FY2026 investing cash flow of $675K (cash outflow) rose 22400.0% year over year, ahead of the +10166.7% change in trailing-twelve-month investing cash flow. Sequentially, it rose 65.0% from the prior quarter. Over 3 fiscal years it compounded at -24.4% a year.
Context
- Investing cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +22400.0% holds above the trailing-twelve-month pace of +10166.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (560K) USD
- Year-over-year change
- -3400.0%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (560K) | -3400.0% |
| FY2024 | 2024-12-31 | (16K) | +94.3% |
| FY2023 | 2023-12-31 | (280K) | +78.4% |
| FY2022 | 2022-12-31 | (1.3M) | +29.3% |
| FY2021 | 2021-12-31 | (1.84M) | — |
Investing Cash Flow vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10166.7% is the highest of 9, against a peer median of -155.1%.
- Over three fiscal years its annual growth of -24.4% compares with a peer median of -38.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $234.28M USD | +993.1% | — | 107.9% | |
| LTM Sep 2026 | $196.53M USD | -379.2% | -43.0% | 51.9% | |
| LTM Mar 2026 | $188.46M USD | -277.0% | +10.7% | — | |
| LTM Mar 2026 | $78.68M USD | -158.5% | — | 50.1% | |
| LTM Mar 2026 | $35.25M USD | -20472.8% | — | 15.5% | |
| LTM Mar 2026 | $33.04M USD | -151.7% | — | — | |
| LTM Mar 2026 | $11.95M USD | +1166.3% | — | — | |
| LTM Mar 2026 | $1.23M USD | +10166.7% | -24.4% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥360.38K CNY | — | -38.8% | — |
GNLXGenelux Corporation | LTM Mar 2026 | $93K USD | +103.2% | — | 1162.5% |
| Peer median (excluding CADL) | — | -155.1% | -38.8% | 51.9% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Depreciation & Amortization | 232K | 778K | 1.28M | 990K | 845K |
| Deferred Income Tax | 11.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Change in Working Capital | (876K) | 71K | (378K) | 346K | 2.19M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 669K | (1.21M) | 45K | (185K) | 802K |
| Other Working Capital | (1.55M) | 1.28M | (378K) | 531K | 1.39M |
| Other Non-Cash Items | 76K | (15.78M) | (301K) | 21.51M | (6.98M) |
| Operating Cash Flow | (22.22M) | (31.42M) | (34.24M) | (27.02M) | (38.31M) |
| Capital Expenditures | (1.84M) | (1.3M) | (457K) | (16K) | (587K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 27K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 177K | 0 | 0 |
| Investing Cash Flow | (1.84M) | (1.3M) | (280K) | (16K) | (560K) |
| Debt Repayment | 0 | 19.91M | 0 | (9.17M) | 36.21M |
| Common Stock Issued | 71.34M | 0 | 0 | 101.76M | 19.89M |
| Common Stock Repurchased | 0 | 0 | (121K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 465K | 64K | 0 | 1.69M | 0 |
| Financing Cash Flow | 71.8M | 19.97M | (121K) | 94.28M | 56.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.75M | (12.74M) | (34.65M) | 67.24M | 17.23M |
| Free Cash Flow | (24.05M) | (32.72M) | (34.7M) | (27.04M) | (38.9M) |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.